Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 16/20 | 0.58 |
| ▸ | CDK2 | P24941 | 16/20 | 0.58 |
| ▸ | CDK5 | Q00535 | 16/20 | 0.58 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.47 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | FPR1 | P21462 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6286973 | 0.81 | CCNE1 (0.49) | CCNE1CDK2CDK5 | |
| SCHEMBL6279222 | 0.80 | CNR1 (0.58) | CCNE1CDK2CDK5 | |
| SCHEMBL6282625 | 0.79 | CDK2 (0.64) | CCNE1CDK2CDK5CDK5R1SMN1; SMN2 | |
| SCHEMBL6281751 | 0.78 | CDK2 (0.90) | CCNE1CDK2CDK5CDK5R1SMN1; SMN2 | |
| SCHEMBL6288008 | 0.75 | CCNE1 (0.63) | CCNE1CDK2CDK5CDK5R1SMN1; SMN2 | |
| SCHEMBL6287954 | 0.75 | CCNE1 (0.63) | CCNE1CDK2CDK5CDK5R1ADORA2A | |
| SCHEMBL6282656 | 0.74 | CCNE1 (0.62) | CCNE1CDK2CDK5CDK5R1SMN1; SMN2 | |
| SCHEMBL5782078 | 0.74 | CDK2 (1.00) | CCNE1CDK2CDK5CDK5R1SMN1; SMN2 | |
| SCHEMBL6285536 | 0.73 | CCNE1 (0.67) | CCNE1CDK2CDK5CDK5R1SMN1; SMN2 | |
| SCHEMBL6282688 | 0.73 | CCNE1 (0.67) | CCNE1CDK2CDK5CDK5R1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157827-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | PEVARELLO PAOLO (IT) | 2004-08-12 | — | — | US | claimed |
| US-20030187040-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | PHARMACIA & UPJOHN SPA (IT) | 2003-10-02 | — | — | US | claimed |
| US-6863647-B2 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | PHARMACIA & UPJOHN S.P.A. (IT) | 2005-03-08 | — | — | US | disclosed |
| US-20040157827-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | PEVARELLO PAOLO (IT) | 2004-08-12 | — | — | US | disclosed |
| US-20030187040-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | PHARMACIA & UPJOHN SPA (IT) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187040-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | UCK2, ULK3, CDK2 | CCNE1 83/4885CDK2 3/4885CDK5 129/4885 |
| US-20040157827-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | UCK2, ULK3, CDK2 | CCNE1 83/4885CDK2 3/4885CDK5 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.